Compare WHG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | SPRO |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 156.3M |
| IPO Year | 2002 | 2017 |
| Metric | WHG | SPRO |
|---|---|---|
| Price | $19.45 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.5K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 203.85 | 111.81 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $97,762,000.00 | $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | $77.08 | ★ N/A |
| Revenue Growth | 3.21 | ★ 39.24 |
| 52 Week Low | $14.70 | $1.08 |
| 52 Week High | $20.97 | $3.08 |
| Indicator | WHG | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 31.65 |
| Support Level | $18.87 | $1.10 |
| Resistance Level | $20.50 | $1.28 |
| Average True Range (ATR) | 0.63 | 0.07 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 54.17 | 48.57 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.